Anzeige
Anzeige

Archive

A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH12-01-0010
Issue: 2012: 108/2 (Aug) pp. 201-403
Pages: 225-235

A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system

Online Supplementary Material

Y.-B. Yu (1, 2, 3), J.-P. Gau (2, 3), C.-Y. Liu (2, 3), M.-H. Yang (2, 3), S.-C. Chiang (4), H.-C. Hsu (1, 2, 3), Y.-C. Hong (2, 3), L.-T. Hsiao (2, 3), J.-H. Liu (2, 3), T.-J. Chiou (2, 3), P.-M. Chen (2, 3), T.-S. Lee (1, 2), L.-F. Chou (5), C.-H. Tzeng (2, 3), T.-J. Chen (2, 6, 7)

(1) Institutes of Physiology, School of Medicine, National Yang-Ming University, Taipei, Taiwan; (2) Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; (3) Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; (4) Information Management Office, Taipei Veterans General Hospital, Taipei, Taiwan; (5) Department of Public Finance, National Chengchi University, Taipei, Taiwan; (6) Hospital and Health Care Administration, School of Medicine, National Yang-Ming University, Taipei, Taiwan; (7) Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

Keywords

Epidemiology, cancer, venous thromboembolism, scoring system

Summary

The Asian population is thought to have a low risk of venous thromboembolism (VTE), but the epidemiology of VTE in cancer patients remains unclear. The National Health Insurance Research Database of Taiwan was used to find hospitalised patients newly-diagnosed with cancer to determine the incidence of VTE in cancer patients and to identify the risk factors for VTE. Between 1997 and 2005, 497,180 cancer patients were identified. During a median follow-up of 21.3 months (range 0–119.9 months), 5,296 patients developed VTE. The estimated incidence was 185 events per 100,000 person-years. Patients with a prior history of VTE and female patients between the ages of 40 and 80 carried high risk of VTE. The rate of VTE was relatively high in patients with myeloma, prostate cancer, lung cancer, gynaecologic cancers, sarcoma, and metastasis of unknown origin. We developed a risk-stratification scoring system to divide the cancer patients into four discrete risk groups (very low risk, low risk, intermediate, and high risk). The incidence of VTE in each group was 0.5%, 0.9%, 1.5%, and 8.7%, respectively (p < 0.001). This scoring system was validated in a separate patient cohort. In conclusion, VTE is a distinct burden for cancer patients in Taiwan. The risk scoring system could prove helpful in decision-making concerning thromboprophylaxis in cancer patients.

You may also be interested in...

1.
Federico Jorge Bottaro 1,3, Maria Cristina Elizondo 1, Carlos Doti 2,3, Julio Enrique Bruetman 1, Pablo Diego Perez Moreno 1, Eduardo Oscar Bullorsky 2,3, Jose Manuel Ceresetto2,3

Thromb Haemost 2008 99 6: 1104-1111

http://dx.doi.org/10.1160/TH07-12-0759

2.

Online Supplementary Material

A. Delluc (1, 2), C. Tromeur (1, 2), F. Le Ven (3), M. Gouillou (4), N. Paleiron (5), L. Bressollette (1, 2), M. Nonent (6), P.-Y. Salaun (1, 2, 3, 4, 5, 6, 7), K. Lacut (1, 2, 3, 4), C. Leroyer (1, 2), G. Le Gal (1, 2, 3, 4), F. Couturaud (1, 2, 4), D. Mottier (1, 2, 3, 4), for the EPIGETBO study group

Thromb Haemost 2016 : -

http://dx.doi.org/10.1160/TH16-03-0205

3.
Who needs prophylaxis and who does not?

C. Ay (1), I. Pabinger (1)

Phlebologie 2016 45 3: 140-145